Literature DB >> 2444299

The influence of atherosclerosis on the mechanical responses of human isolated coronary arteries to substance P, isoprenaline and noradrenaline.

G Berkenboom1, M Depierreux, J Fontaine.   

Abstract

1 The responses to substance P, isoprenaline and noradrenaline were observed on human isolated coronary arteries removed from 30 human hearts, and were classified according to the age of the hearts, the presence or absence of cardiac failure and the degree of atherosclerosis. 2 The endothelium-dependent vasodilator, substance P (0.1 microM), relaxed rings precontracted with prostaglandin F2 alpha, (PGF2 alpha, 1 microM) when they were devoid of atherosclerosis. The presence of moderate or severe lesions of atherosclerosis abolished this response. There was no difference in the response, related to either the age of the hearts or to the presence or absence of cardiac failure. 3 The dose-response curves to isoprenaline (an endothelium-independent vasodilator) were also markedly altered by the presence of atherosclerotic lesions, while aging and the presence of cardiac failure did not alter the maximal relaxation. These last 2 factors induced only a rightward shift of the dose-response curves. 4 On severely atherosclerotic rings, beta-adrenoceptor-mediated responses were so altered that the effect of noradrenaline was wholly vasoconstrictor (via alpha-adrenoceptors). This response was not modified after pretreatment with atenolol (10 microM). 5 It is concluded that atherosclerosis in human coronary arteries, induces alterations in the responses to substance P and to beta-adrenoceptor agonists. The beta-adrenoceptor-mediated relaxations seem more influenced by the presence of atherosclerosis than they are by aging or by the down-regulation induced by cardiac failure. Conversely, the alpha-adrenoceptor responses appear to be well preserved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444299      PMCID: PMC1853620          DOI: 10.1111/j.1476-5381.1987.tb11302.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Coronary artery cyclic AMP content during adrenergic receptor stimulation.

Authors:  C L Seidel; R L Schnarr; H V Sparks
Journal:  Am J Physiol       Date:  1975-08

Review 2.  The pathogenesis of atherosclerosis (second of two parts).

Authors:  R Ross; J A Glomset
Journal:  N Engl J Med       Date:  1976-08-19       Impact factor: 91.245

3.  Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity.

Authors:  D Papahadjopoulos; M Cowden; H Kimelberg
Journal:  Biochim Biophys Acta       Date:  1973-11-30

4.  High efficiency coupling between beta-adrenergic receptors and cardiac contractility: direct evidence for "spare" beta-adrenergic receptors.

Authors:  J C Venter
Journal:  Mol Pharmacol       Date:  1979-09       Impact factor: 4.436

5.  Biochemistry of atherosclerosis produced by cholesterol feeding, thrombosis, and injury.

Authors:  B I Weigensberg; J Lough; R H More
Journal:  Exp Mol Pathol       Date:  1982-10       Impact factor: 3.362

6.  Reflex increase in coronary vascular resistance in patients with ischemic heart disease.

Authors:  G H Mudge; W Grossman; R M Mills; M Lesch; E Braunwald
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

7.  Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

Authors:  W S Colucci; R W Alexander; G H Williams; R E Rude; B L Holman; M A Konstam; J Wynne; G H Mudge; E Braunwald
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245

8.  Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris.

Authors:  U Thadani; C Davidson; W Singleton; S H Taylor
Journal:  N Engl J Med       Date:  1979-04-05       Impact factor: 91.245

9.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

10.  Alternative mechanisms for the potentiation of the relaxation evoked by isoprenaline in aortae from young and aged rats.

Authors:  T Godfraind
Journal:  Eur J Pharmacol       Date:  1979-01-15       Impact factor: 4.432

View more
  7 in total

1.  Study of ridazolol on isolated canine and human coronary arteries.

Authors:  P Unger; G Berkenboom; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

2.  Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor.

Authors:  Andrew P Davie; John J V McMurray
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

3.  Immunohistochemical and ultrastructural localisation of peptide-containing nerves and myocardial cells in the human atrial appendage.

Authors:  J Wharton; S Gulbenkian; A Merighi; D M Kuhn; R Jahn; K M Taylor; J M Polak
Journal:  Cell Tissue Res       Date:  1988-10       Impact factor: 5.249

4.  Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro.

Authors:  A Ferro; L R Queen; R M Priest; B Xu; J M Ritter; L Poston; J P Ward
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

5.  Effects of nitric oxide synthase inhibitors, L-NG-nitroarginine and L-NG-nitroarginine methyl ester, on responses to vasodilators of the guinea-pig coronary vasculature.

Authors:  A Vials; G Burnstock
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

Review 6.  Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.

Authors:  L J Ignarro; G Ross; J Tillisch
Journal:  West J Med       Date:  1991-01

7.  Nitric oxide function in atherosclerosis.

Authors:  K E Matthys; H Bult
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.